Straits Times Index
3,289.42 -23.93 (-0.72%) S&P 500
5,300.43 +53.75 (+1.02%) Dow
39,824.63 +266.52 (+0.67%) Nasdaq
16,729.32 +218.14 (+1.32%) Bitcoin USD
65,450.30 +4,121.32 (+6.72%) CMC Crypto 200
1,378.81 +110.86 (+8.74%)
Eupraxia Pharmaceuticals Inc. (EPRX.TO)
- PR Newswire
Eupraxia Pharmaceuticals to Present Initial Results from Ongoing Phase 1b Study of EP-104GI for the Treatment of Eosinophilic Esophagitis at Upcoming Digestive Disease Week Annual Meeting 2024
Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology to optimize drug delivery for applications with significant unmet need, today announced that initial results from the ongoing Phase 1b study of EP-104GI for the treatment of eosinophilic esophagitis will be presented at the upcoming Digestive Disease Week ("DDW") Annual Meeting 2024.
- CNW Group
Eupraxia Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update
Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ: EPRX) (TSX: EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology to optimize drug delivery for applications with significant unmet need, today announced its financial results for the first quarter of 2024 and provided a corporate update.
- CNW Group
Eupraxia Pharmaceuticals Announces Gastrointestinal Clinical Advisory Board
Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology to optimize drug delivery for applications with significant unmet need, today announced the formation of a Clinical Advisory Board for its gastrointestinal ("GI") program. The Clinical Advisory Board is comprised of Dr. Evan Dellon (Chairman), Dr. Stephen Attwood, Dr. Albert Bredenoord, Dr. Donna Griebel, Dr. Ikuo Hirano
